<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM12980</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-12980</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Studies</subject></subj-group></article-categories><title-group><article-title>Т-лимфоциты FoxP3+ и их взаимосвязь с выраженностью коронарного атеросклероза у пациентов с ишемической болезнью сердца и сахарным диабетом 2 типа: пилотное исследование</article-title><trans-title-group xml:lang="en"><trans-title>T-lymphocytes FoxP3+ and their interconnection with the severity of coronary atherosclerosis in patients with coronary artery disease and diabetes mellitus type 2: a pilot study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4537-0008</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кологривова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kologrivova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кологривова Ирина Вячеславовна - кандидат медицинских наук; Researcher ID: G-3047-2014; Scopus Author ID: 56072496100.</p><p>634012, Томск, ул. Киевская, д. 111А</p></bio><bio xml:lang="en"><p>Irina V. Kologrivova - MD, PhD; Researcher ID: G-3047-2014; Scopus Author ID: 56072496100.</p><p>111A Kievskaya street, 634012, Tomsk</p></bio><email xlink:type="simple">ikologrivova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6679-1269</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кошельская</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Koshelskaya</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кошельская Ольга Анатольевна - доктор медицинских наук, профессор; Researcher ID: M-4339-2016; Scopus Author ID: 6507133262.</p><p>Томск</p></bio><bio xml:lang="en"><p>Olga A. Koshelskaya - MD, PhD, Professor. ; Researcher ID: M-4339-2016; Scopus Author ID: 6507133262.</p><p>Tomsk</p></bio><email xlink:type="simple">koshel@live.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9645-6720</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суслова</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Suslova</surname><given-names>T. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Суслова Татьяна Евгеньевна - кандидат медицинских наук; Researcher ID: M-4339-2016; Scopus Author ID: 7003396715.</p><p>Томск</p></bio><bio xml:lang="en"><p>Tatiana E. Suslova - MD, PhD; Researcher ID: M-4339-2016; Scopus Author ID: 7003396715.</p><p>Tomsk</p></bio><email xlink:type="simple">tes@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2818-5882</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Харитонова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kharitonova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Харитонова Ольга Анатольевна - Researcher ID: GXN-0625-2022; Scopus Author ID: 57208859569.</p><p>Томск</p></bio><bio xml:lang="en"><p>Olga A. Kharitonova - MD; Researcher ID: GXN-0625-2022; Scopus Author ID: 57208859569.</p><p>Tomsk</p></bio><email xlink:type="simple">hoa@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1253-3352</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трубачева</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Trubacheva</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трубачева Оксана Александровна - кандидат медицинских наук; Researcher ID: R-6245-2016; Scopus Author ID: 56072599700.</p><p>Томск</p></bio><bio xml:lang="en"><p>Oksana A. Trubacheva - MD, PhD; Researcher ID: R-6245-2016; Scopus Author ID: 56072599700.</p><p>Tomsk</p></bio><email xlink:type="simple">OATrubacheva@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1235-9956</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кравченко</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kravchenko</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кравченко Елена Сергеевна - Researcher ID: L-7723-2016; Scopus Author ID: 56583748500.</p><p>Томск</p></bio><bio xml:lang="en"><p>Elena S. Kravchenko - MD; Researcher ID: L-7723-2016; Scopus Author ID: 56583748500.</p><p>Tomsk</p></bio><email xlink:type="simple">nikonovaes@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6924-966X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дмитрюков</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dmitriukov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дмитрюков Алексей Александрович - Researcher ID: HGE-4159-2022.</p><p>Томск</p></bio><bio xml:lang="en"><p>Alexey A. Dmitriukov - Researcher ID: HGE-4159-2022.</p><p>Tomsk</p></bio><email xlink:type="simple">aldmn9k@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук; Сибирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>14</day><month>07</month><year>2023</year></pub-date><volume>26</volume><issue>3</issue><fpage>213</fpage><lpage>223</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кологривова И.В., Кошельская О.А., Суслова Т.Е., Харитонова О.А., Трубачева О.А., Кравченко Е.С., Дмитрюков А.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Кологривова И.В., Кошельская О.А., Суслова Т.Е., Харитонова О.А., Трубачева О.А., Кравченко Е.С., Дмитрюков А.А.</copyright-holder><copyright-holder xml:lang="en">Kologrivova I.V., Koshelskaya O.A., Suslova T.E., Kharitonova O.A., Trubacheva O.A., Kravchenko E.S., Dmitriukov A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/12980">https://www.dia-endojournals.ru/jour/article/view/12980</self-uri><abstract><sec><title>ОБОСНОВАНИЕ</title><p>ОБОСНОВАНИЕ. Одним из связующих патогенетических звеньев сахарного диабета 2 типа (СД2) и ишемической болезни сердца (ИБС) является хроническое низкоинтенсивное воспаление, которое ограничивают FoxP3+ Т-регуляторные лимфоциты.</p></sec><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Изучить содержание FoxP3+CD25hi и FoxP3+CD25lo T-лимфоцитов, субклеточной локализации FoxP3 и продукцию регуляторных цитокинов во взаимосвязи с клинико-метаболическими параметрами у пациентов с ИБС и СД2.</p></sec><sec><title>МАТЕРИАЛЫ И МЕТОДЫ</title><p>МАТЕРИАЛЫ И МЕТОДЫ. Проведено наблюдательное одноцентровое одномоментное сравнительное исследование. Тяжесть атеросклероза оценивали путем расчета индекса Gensini Score по данным селективной коронароангиографии. Методом проточной цитометрии оценивали абсолютное и относительное содержание CD4+CD25hiFoxP3+ и CD4+CD25loFoxP3+ Т-лимфоцитов в крови. Методом проточной цитометрии с визуализацией определяли перенос FoxP3 в ядро клеток. Методом мультиплексного анализа оценивали содержание цитокинов в сыворотке крови и надосадочной жидкости культур мононуклеарных лейкоцитов.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Обследованы 57 пациентов с хронической ИБС, из них у 22 пациентов был диагностирован СД2. У пациентов с ИБС и СД2 было повышено содержание FoxP3+CD25lo-клеток по сравнению с пациентами с ИБС без диабета (1,15 (0,98; 1,73) против 0,96 (0,60; 1,15)% (р=0,046); 1,48 (1,05; 1,97) против 1,07 (0,71; 1,42)×107/л (р=0,025)). Пациенты с СД2 характеризовались более высоким уровнем переноса фактора FoxP3 в ядро FoxP3+CD25lo-клеток (92,0 (86,4; 95,0) против 88,7 (80,0; 91,4)%, р=0,040) и повышением содержания хемокина CCL22 в сыворотке крови (912 (828; 1061) против 669 (585; 738) пг/мл, р=0,022) и надосадочной жидкости стимулированных липополисахаридом (ЛПС) культур мононуклеарных лейкоцитов (1189 (851; 1310) против 539 (437; 949) пг/мл, р=0,038), что коррелировало с содержанием CD4+CD25hiFoxP3+ клеток (Rs=0,587; p=0,044) и индексом триглицериды/глюкоза (Rs=0,587; p=0,044). Выявленные изменения были наиболее выражены у пациентов с умеренно повышенными значениями Gensini Score (17–45  баллов).</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. Мы впервые показали взаимосвязь между увеличением содержания FoxP3+CD25lo-лимфоцитов в периферической крови и доли FoxP3+CD25lo-лимфоцитов с ядерным расположением FoxP3 с выраженностью атеросклероза у пациентов с сочетанием ИБС и СД2. Эти данные обосновывают необходимость дальнейших исследований FoxP3+CD25lo-клеток с целью подтверждения их диагностической ценности в качестве маркера воспалительного ответа в тканях.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: One of the common pathogenic links of diabetes mellitus type 2 (T2DM) and coronary artery disease (CAD) is chronic low-grade inflammation, restricted by FoxP3+ T-regulatory lymphocytes.</p></sec><sec><title>AIM</title><p>AIM: To investigate the numbers of FoxP3+CD25hi and FoxP3+CD25lo T-lymphocytes, the subcellular localization of FoxP3 in them, and the production of the main cytokines in relation to clinical and metabolic parameters in patients with association of CAD and T2DM.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: An observational single-center single-stage comparative study was conducted. The severity of atherosclerosis was assessed by calculating the Gensini Score index after coronary angiography. Absolute numbers and frequencies of CD4+CD25hiFoxP3+ and CD4+CD25loFoxP3+ T-lymphocytes were assessed in peripheral blood by flow cytometry. Imaging flow cytometry was used to determine the degree of FoxP3 translocation to the cell’s nucleus. Concentration of cytokines in blood serum and supernatants of mononuclear leukocytes’ cultures was determined by the multiplex analysis.</p></sec><sec><title>RESULTS</title><p>RESULTS: We recruited 57 patients with chronic CAD. Of these, T2DM was diagnosed in 22 patients. In patients with CAD and T2DM, the absolute numbers and frequencies of FoxP3+CD25lo cells were increased compared to patients with CAD without diabetes (1.15 (0.98; 1.73) vs. 0.96 (0.60; 1.15)% (р=0.046); 1.48 (1.05; 1.97) vs. 1.07 (0.71; 1.42) x107/L (р=0.025)). Patients with T2DM also had a higher level of translocation of FoxP3 to the nucleus of FoxP3+CD25lo cells (92.0 (86.4; 95.0) vs. 88.7 (80.0; 91.4)%, р=0.040) and increased concentration of the chemokine CCL22 both in blood serum (912 (828; 1061) vs. 669 (585; 738) pg/mL, р=0.022) and supernatants of LPS-stimulated mononuclear leukocyte cultures (1189 (851; 1310) vs. 539 (437; 949) pg/mL, р=0.038), which correlated with the presence of CD4+CD25hiFoxP3+ cells (Rs=0.587; p=0.044) and the triglyceride/glucose index (Rs=0.587; p=0.044). The identified changes were most pronounced in patients with moderately elevated values on the Gensini Score (17–45 points).</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION: We are the first to show association between the numbers of FoxP3+CD25lo-lymphocytes in peripheral blood and an increase in the nuclear translocation of FoxP3 in them with the severity of atherosclerosis in patients with association of CAD and T2DM. These data justify the necessity of the further investigation of the diagnostic significance of FoxP3+CD25lo-cells as biomarkers of tissue inflammation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>атеросклероз</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>FoxP3+ Т-лимфоциты</kwd><kwd>CCL22 хемокин</kwd><kwd>Gensini Score</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atherosclerosis</kwd><kwd>diabetes mellitus type 2</kwd><kwd>FoxP3+ T-lymphocytes</kwd><kwd>CCL22 chemokine</kwd><kwd>Gensini Score</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках фундаментального научного исследования №122020300043-1</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Poznyak A, Grechko AV, Poggio P, et al. The diabetes mellitusatherosclerosis connection: The role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21(5):1835. doi: https://doi.org/10.3390/ijms21051835</mixed-citation><mixed-citation xml:lang="en">Poznyak A, Grechko AV, Poggio P, et al. The diabetes mellitusatherosclerosis connection: The role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21(5):1835. doi: https://doi.org/10.3390/ijms21051835</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. doi: https://doi.org/10.1056/NEJMoa0806470</mixed-citation><mixed-citation xml:lang="en">Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. doi: https://doi.org/10.1056/NEJMoa0806470</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen. Circulation. 2012;126(23):2739-2748. doi: https://doi.org/10.1161/CIRCULATIONAHA.112.122556</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen. Circulation. 2012;126(23):2739-2748. doi: https://doi.org/10.1161/CIRCULATIONAHA.112.122556</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T Cells. Arterioscler Thromb Vasc Biol. 2015;35(2):280-287. doi: https://doi.org/10.1161/ATVBAHA.114.303568</mixed-citation><mixed-citation xml:lang="en">Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T Cells. Arterioscler Thromb Vasc Biol. 2015;35(2):280-287. doi: https://doi.org/10.1161/ATVBAHA.114.303568</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ou Hx, Guo Bb, Liu Q, et al. Regulatory T Cells as a new therapeutic target for atherosclerosis. Acta Pharmacol Sin. 2018;39(8):1249-1258. doi: https://doi.org/10.1038/aps.2017.140</mixed-citation><mixed-citation xml:lang="en">Ou Hx, Guo Bb, Liu Q, et al. Regulatory T Cells as a new therapeutic target for atherosclerosis. Acta Pharmacol Sin. 2018;39(8):1249-1258. doi: https://doi.org/10.1038/aps.2017.140</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Qiao Y, Shen J, He L, et al. Changes of regulatory T Cells and of proinflammatory and immunosuppressive cytokines in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. J Diabetes Res. 2016;2016(23):1-19. doi: https://doi.org/10.1155/2016/3694957</mixed-citation><mixed-citation xml:lang="en">Qiao Y, Shen J, He L, et al. Changes of regulatory T Cells and of proinflammatory and immunosuppressive cytokines in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. J Diabetes Res. 2016;2016(23):1-19. doi: https://doi.org/10.1155/2016/3694957</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Magg T, Mannert J, Ellwart JW, et al. Subcellular localization of FOXP3 in human regulatory and nonregulatory T Cells. Eur J Immunol. 2012;42(6):1627-1638. doi: https://doi.org/10.1002/eji.201141838</mixed-citation><mixed-citation xml:lang="en">Magg T, Mannert J, Ellwart JW, et al. Subcellular localization of FOXP3 in human regulatory and nonregulatory T Cells. Eur J Immunol. 2012;42(6):1627-1638. doi: https://doi.org/10.1002/eji.201141838</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ferreira RC, Simons HZ, Thompson WS, et al. Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity. J Autoimmun. 2017;84(23):75-86. doi: https://doi.org/10.1016/j.jaut.2017.07.009</mixed-citation><mixed-citation xml:lang="en">Ferreira RC, Simons HZ, Thompson WS, et al. Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity. J Autoimmun. 2017;84(23):75-86. doi: https://doi.org/10.1016/j.jaut.2017.07.009</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (10-й выпуск) // Сахарный диабет. — 2021. — Т. 24. — №S1. — С. 1-235. doi: https://doi.org/10.14341/DM12802</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2021;24(S1):1-235 (In Russ.). doi: https://doi.org/10.14341/DM12802</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Huebschmann AG, Huxley RR, Kohrt WM, et al. Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia. 2019;62(10):1761-1772. doi: https://doi.org/10.1007/s00125-019-4939-5</mixed-citation><mixed-citation xml:lang="en">Huebschmann AG, Huxley RR, Kohrt WM, et al. Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia. 2019;62(10):1761-1772. doi: https://doi.org/10.1007/s00125-019-4939-5</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wang K-Y, Zheng Y-Y, Wu T-T, et al. Predictive value of gensini score in the long-term outcomes of patients with coronary artery disease who underwent PCI. Front Cardiovasc Med. 2022;8(10):1761-1772. doi: https://doi.org/10.3389/fcvm.2021.778615</mixed-citation><mixed-citation xml:lang="en">Wang K-Y, Zheng Y-Y, Wu T-T, et al. Predictive value of gensini score in the long-term outcomes of patients with coronary artery disease who underwent PCI. Front Cardiovasc Med. 2022;8(10):1761-1772. doi: https://doi.org/10.3389/fcvm.2021.778615</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zi C, He L, Yao H, et al. Changes of Th17 cells, regulatory T cells, Treg/Th17, IL-17 and IL-10 in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Endocrine. 2022;76(2):263-272. doi: https://doi.org/10.1007/s12020-022-03043-6</mixed-citation><mixed-citation xml:lang="en">Zi C, He L, Yao H, et al. Changes of Th17 cells, regulatory T cells, Treg/Th17, IL-17 and IL-10 in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Endocrine. 2022;76(2):263-272. doi: https://doi.org/10.1007/s12020-022-03043-6</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Guzmán-Flores JM, Ramírez-Emiliano J, PérezVázquez V, López-Briones S. Th17 and regulatory T cells in patients with different time of progression of type 2 diabetes mellitus. Cent Eur J Immunol. 2020;45(1):29-36. doi: https://doi.org/10.5114/ceji.2020.94670</mixed-citation><mixed-citation xml:lang="en">Guzmán-Flores JM, Ramírez-Emiliano J, PérezVázquez V, López-Briones S. Th17 and regulatory T cells in patients with different time of progression of type 2 diabetes mellitus. Cent Eur J Immunol. 2020;45(1):29-36. doi: https://doi.org/10.5114/ceji.2020.94670</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Toulza F, Nosaka K, Tanaka Y, et al. Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional Foxp3+ regulatory T Cells. J Immunol. 2010;185(1):183-189. doi: https://doi.org/10.4049/jimmunol.0903846.14</mixed-citation><mixed-citation xml:lang="en">Toulza F, Nosaka K, Tanaka Y, et al. Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional Foxp3+ regulatory T Cells. J Immunol. 2010;185(1):183-189. doi: https://doi.org/10.4049/jimmunol.0903846.14</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Handke J, Kummer L, Weigand MA, Larmann J. Modulation of peripheral CD4+CD25+Foxp3+regulatory T cells ameliorates surgical stress-induced atherosclerotic plaque progression in ApoE-deficient mice. Front Cardiovasc Med. 2021;8(2):263-272. doi: https://doi.org/10.3389/fcvm.2021.682458</mixed-citation><mixed-citation xml:lang="en">Handke J, Kummer L, Weigand MA, Larmann J. Modulation of peripheral CD4+CD25+Foxp3+regulatory T cells ameliorates surgical stress-induced atherosclerotic plaque progression in ApoE-deficient mice. Front Cardiovasc Med. 2021;8(2):263-272. doi: https://doi.org/10.3389/fcvm.2021.682458</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Frenkel JDH, Ackart DF, Todd AK, et al. Metformin enhances protection in guinea pigs chronically infected with Mycobacterium tuberculosis. Sci Rep. 2020;10(1):16257. doi: https://doi.org/10.1038/s41598-020-73212-y</mixed-citation><mixed-citation xml:lang="en">Frenkel JDH, Ackart DF, Todd AK, et al. Metformin enhances protection in guinea pigs chronically infected with Mycobacterium tuberculosis. Sci Rep. 2020;10(1):16257. doi: https://doi.org/10.1038/s41598-020-73212-y</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Amin D, Richa T, Mollaee M, et al. Metformin effects on FOXP3+ and CD8+ T cell infiltrates of head and neck squamous cell carcinoma. Laryngoscope. 2020;130(9):E490-E498. doi: https://doi.org/10.1002/lary.28336</mixed-citation><mixed-citation xml:lang="en">Amin D, Richa T, Mollaee M, et al. Metformin effects on FOXP3+ and CD8+ T cell infiltrates of head and neck squamous cell carcinoma. Laryngoscope. 2020;130(9):E490-E498. doi: https://doi.org/10.1002/lary.28336</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
